MedImmune and Sanofi Pasteur are creating and marketing MEDI8897, a drug that aims to prevent lower respiratory tract illnesses that stem from respiratory syncytial virus.
Respiratory syncytial virus, which has symptoms that are related to colds, leads the way when it comes to what gives children and infants lower respiratory tract illness.